Therapeutic effects of ranibizumab in neovascular age-related macular degeneration

Author: Ciulla, Thomas A

Source: Expert Review of Ophthalmology, Volume 2, Number 5, October 2007 , pp. 679-693(15)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Vision loss due to age-related macular degeneration (AMD) is a major public health issue that significantly impacts the quality of life of affected individuals and their families. Recently approved anti-VEGF agents have shown promise as treatment options for the neovascular form of AMD. At present, ranibizumab is the most promising US FDA-approved treatment for neovascular AMD, with noteworthy effects on vision improvement and stabilization. The safety and efficacy of ranibizumab for the treatment of neovascular AMD were established in several pivotal clinical trials, including the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA), and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) trials. Ranibizumab is being further investigated as a potential therapy for other indications, including diabetic macular edema, retinal vein occlusion and presumed ocular histoplasmosis syndrome.

Keywords: age-related macular degeneration; choroidal neovascularization; ranibizumab; retina; vascular endothelial growth factor A

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469899.2.5.679

Publication date: 2007-10-01

More about this publication?

Expert Review of Ophthalmology provides an important platform for commentary and debate on current and emerging approaches in ocular medicine.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites